Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02687971
Recruitment Status : Completed
First Posted : February 23, 2016
Last Update Posted : September 12, 2019
Information provided by (Responsible Party):
Drugs for Neglected Diseases

Tracking Information
First Submitted Date  ICMJE February 17, 2016
First Posted Date  ICMJE February 23, 2016
Last Update Posted Date September 12, 2019
Actual Study Start Date  ICMJE December 2016
Actual Primary Completion Date August 10, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 17, 2016)
Initial cure rate [ Time Frame: Day 90, after start of treatment ]
Initial Cure: Ulcerated lesions: 100% re-epithelialization of the lesion(s) by Day 90. Non-Ulcerated lesions: flattening and/or no signs of induration of the lesion(s) by Day 90. The percentage of re-epithelialization of the lesion(s) is calculated by comparing the size of the ulcer at Day 7 against the size at the follow up visit
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02687971 on Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 17, 2016)
  • Final cure rate [ Time Frame: Day 180, after star of treatment ]
    The number of patients who fulfill the criteria of initial cure and have no relapse by Day 180
  • Frequency and severity of AEs [ Time Frame: Day 45 ]
    Frequency and severity of AEs by treatment group
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨
Official Title  ICMJE A Randomized, Open Label, Multicenter Study to Determine the Efficacy and Safety of Combining Thermotherapy and a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨
Brief Summary The purpose of this trial is to determine the efficacy and safety of a combined therapy using thermotherapy (TT) (one session, 50 degrees Celsius for 30") + miltefosine at a standard dose of 2.5 mg/kg/day for 21 days for the treatment of uncomplicated CL in Peru and Colombia
Detailed Description

The use of topical treatments for Cutaneous leishmaniasis (CL) is an option that has been widely explored and it is currently listed as an options by WHO in those situations where the patient has few lesions (≤ 4) of less than ≤ 4 cm in diameter and located in areas of the body which may be treated topically.

Local heat, especially the one produced by radio frequency waves (Themo-Med®) has been widely tested for CL in both Old and New World. The advantages of using thermotherapy include: 1) high security profile; 2) only one session is required which ensures compliance with treatment; 3) easy to use in the field since the machine operates with batteries; 4) its effectiveness does not depend on the species of Leishmania causing the lesion as it is a physical measure; and 5) it can be used in patients in whom systemic treatment with antimonials are contraindicated, including women who are pregnant or breastfeeding. In the New World, Thermo-Med® has been evaluated in Mexico, Guatemala, Colombia and Brazil (all but one were randomized clinical trials), reporting cure rates of 90%, 73%, 64% and 75% respectively

There are no clinical trials evaluating the efficacy of miltefosine for CL when given for less than 20 days. The 21-day course was chosen to give the best chances to the combination approach and based on a) the results of a Phase II trial conducted in Colombia showing that a mean dose of miltefosine of 133 mg/day/20 days resulted in a cure rate of 82%20 and; b) a report showing that the a daily administration of 100 mg/day (2.5 mg/kg of body weight/day for 28 days) resulted in a mean maximum concentration of drug in serum at day 23 of treatment of 70,000 ng/ml21.

The theoretical advantages offered by this combination are that a) we are using two approaches that are currently recommended for use individually and for which there is good information regarding their efficacy and safety when used alone; b) the use of a topical plus a systemic treatment would hypothetically have an additive effect, since systemic treatment would eliminate those circulating or remaining parasites located in the periphery of the lesion that topical treatment fails to remove and which might be the cause of relapses22,23; c) it offers the opportunity to increase the current cure rate reported with any other treatment approach available when used alone; d) it will reduce the length of treatment with miltefosine and hopefully the cost and rates of adverse events associated with 28 days of treatment with miltefosine.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Cutaneous Leishmaniasis
Intervention  ICMJE Drug: Miltefosine
Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
Other Name: Impavido
Study Arms  ICMJE
  • Active Comparator: Thermotherapy alone
    Local heat will be applied using a Localized Current Field radio-frequency generating device manufactured by Thermo-Med Technologies, Inc. A wand with 2 electrodes is connected to the main housing by a thin wire. The electrodes are applied to the skin. We will use electrodes 6 mm long, separated by 4 mm. One single session at the site of the lesion(s) at 50°C for 30" applications will be used. Depending on the size of the lesion, more than one application may be administered.
    Intervention: Drug: Miltefosine
  • Experimental: Thermotherapy plus Miltefosine

    In addition to receiving one single session of thermotherapy as described above, subjects will receive oral miltefosine two or three capsules a day, which is the equivalent of 100 to 150mg respectively for 21 days. Miltefosine capsules will be taken after breakfast, lunch and dinner, in other words, after food.

    The daily dose of miltefosine will depend on the weight of each patient. According to dosage instructions if the patient is taking the miltefosine twice a day, it must be taken in the morning and night (dose of 100mg/Kg/day). Whereas if the patient is taking miltefosine three times a day, it must be taken in the morning, noon and night (dose of 150mg/Kg/day).

    Intervention: Drug: Miltefosine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 17, 2016)
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE September 10, 2019
Actual Primary Completion Date August 10, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Patient with a confirmed diagnosis of CL in at least one lesion by at least one of the following methods: 1) microscopic identification of amastigotes in stained lesion tissue, or 2) demonstration of Leishmania by PCR, or 3) positive culture for promastigotes,

Patient has a lesion that satisfies the following criteria:

  • Lesion size ≥ 0.5 cm and </= 4 cm (Longest diameter),
  • Not located on the ear, face, close to mucosal membranes, joints or on a location that in the opinion of the PI is difficult to apply TT,
  • Patient with </= 4 CL lesions,
  • Duration of lesion less than 4 months by patient history, Patient able to give written informed consent, In the opinion of the investigator, the patient is capable of understanding and complying with the protocol

Exclusion Criteria:

  • Female with a positive urine pregnancy test at screening or who is breast feeding, lactating or female at fertile age who does not agree to take appropriate contraception during treatment period and up to D90,
  • History of clinically significant medical problems / treatment that might interact, either negatively or positively, with topical treatment of leishmaniasis including any immunocompromising condition,
  • Within 8 weeks (56 days) of trial Day 1, received treatment for leishmaniasis with any medication including antimonials likely, in the opinion of the PI, to modify the course of the Leishmania infection,
  • Has diagnosis or suspected diagnosis of mucocutaneous leishmaniasis based on physical exam,
  • History of known or suspected hypersensitivity or idiosyncratic reactions to trial medication or exipients,
  • Patient who is not willing to attend the trial visits, or is not able to comply with follow-up visits up to 6 months,
  • Known history of drug addiction and/or alcohol abuse
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Colombia,   Peru
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT02687971
Other Study ID Numbers  ICMJE DNDi-MILT-07-CL
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Drugs for Neglected Diseases
Study Sponsor  ICMJE Drugs for Neglected Diseases
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Ivan Dario Velez, Prof PECET, Universidad de Antioquia, Medellin, Colombia
Principal Investigator: Alejandro Llanos-Cuentas, MD, PhD Universidad Peruana Cayetano Heredia, Lima, Peru
PRS Account Drugs for Neglected Diseases
Verification Date September 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP